The meeting was called after the blood-testing startup, which has been a Walgreens partner since 2013, came under fire when a WSJ report earlier this month alleged Theranos may have overstated its achievements. The company called the article factually and scientifically inaccurate, but decided to pause use of its proprietary technology for all but one blood test following unannounced FDA inspections.
Walgreens officials found out about Theranos pulling back its testingand the FDA inspections through articles in the WSJ, according to the report.
The companies are continuing discussions, but have halted plans to expand their partnership beyond the 41 Walgreens stores in Arizona and California, according to the report. A spokesperson from Walgreens did not provide WSJ with a comment on the partnership with Theranos.
However, people familiar with the matter told WSJ the pharmacy chain has formed a small team to investigate the claims made in the two articles, according to the report.
“We’re trying to figure out where we are and what we do going forward. We need to understand the truth,” a Walgreens official told WSJ.
More articles on leadership and management:
Theranos’ Elizabeth Holmes speaks out: 10 things to know
Which presidential candidate do the most CEOs donate to?
50 top business schools: As ranked by Bloomberg
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.